[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454603":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":175,"collaborators":27,"id":177,"slug":178,"hasResults":179,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":179,"sex":185,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":27,"studyType":191,"phases":192,"briefSummary":194,"conditions":195,"keywords":27,"overallStatus":44,"whyStopped":27,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Participants with body weight ≥10kg to \u003C20kg","EXPERIMENTAL","Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients",[13],"Drug: Satralizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 Participants with body weight ≥20kg to \u003C40kg","Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.",[13],{"label":19,"type":10,"description":16,"interventionNames":20},"Cohort 3 Participants with body weight ≥40kg",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Satralizumab","Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.",[9,15,19],null,[29],{"name":30,"affiliation":5,"role":31},"Clinical Trials","STUDY_DIRECTOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":27,"email":37},"Reference Study ID Number: WN41733 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S.)","global-roche-genentech-trials@gene.com",{"name":39,"role":35,"phone":27,"phoneExt":27,"email":40},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry","global.medical_information@roche.com",[42,56,62,71,83,93,104,116,126,133,145,154,164],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":27},"Children's Hospital Colorado.","RECRUITING","Denver","Colorado","80218-1007","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-104.9847,39.73915,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":27,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":27,"geoPoint":27,"contacts":27},"Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan","Ciudad Autonoma Buenos Aires","C1249ABN","Argentina","AR",{"facility":63,"status":44,"city":64,"state":27,"zip":65,"country":60,"countryCode":61,"cosmosGeoPoint":66,"geoPoint":70,"contacts":27},"Clinica Universitaria Reina Fabiola","Córdoba","X5004FHP",{"type":51,"coordinates":67},[68,69],-64.18853,-31.40648,{"lat":69,"lon":68},{"facility":72,"status":44,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":27},"Guangzhou Women and Children's Medical Center","Guangzhou","Guangdong","510120","China","CN",{"type":51,"coordinates":79},[80,81],113.25,23.11667,{"lat":81,"lon":80},{"facility":84,"status":44,"city":85,"state":86,"zip":87,"country":76,"countryCode":77,"cosmosGeoPoint":88,"geoPoint":92,"contacts":27},"Children's Hospital of Fudan University","Shanghai","Shanghai Municipality","201102",{"type":51,"coordinates":89},[90,91],121.45806,31.22222,{"lat":91,"lon":90},{"facility":94,"status":44,"city":95,"state":27,"zip":96,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":103,"contacts":27},"Centre Hospitalier Universitaire de Bicêtre","Le Kremlin-Bicêtre","94275","France","FR",{"type":51,"coordinates":100},[101,102],2.36073,48.81471,{"lat":102,"lon":101},{"facility":105,"status":44,"city":106,"state":107,"zip":108,"country":109,"countryCode":110,"cosmosGeoPoint":111,"geoPoint":115,"contacts":27},"IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN","Rome","Lazio","00165","Italy","IT",{"type":51,"coordinates":112},[113,114],12.51133,41.89193,{"lat":114,"lon":113},{"facility":117,"status":44,"city":118,"state":119,"zip":120,"country":109,"countryCode":110,"cosmosGeoPoint":121,"geoPoint":125,"contacts":27},"Fondazione Istituto Neurologico Mondino IRCCS","Pavia","Lombardy","27100",{"type":51,"coordinates":122},[123,124],9.15917,45.19205,{"lat":124,"lon":123},{"facility":127,"status":44,"city":128,"state":129,"zip":130,"country":131,"countryCode":132,"cosmosGeoPoint":27,"geoPoint":27,"contacts":27},"Grupo Medico Camino","DF","Mexico CITY (federal District)","DUMMY_VALUE","Mexico","MX",{"facility":134,"status":135,"city":136,"state":27,"zip":137,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":27},"Uniwersyteckie Centrum Kliniczne","ACTIVE_NOT_RECRUITING","Gdansk","80-214","Poland","PL",{"type":51,"coordinates":141},[142,143],18.64912,54.35227,{"lat":143,"lon":142},{"facility":146,"status":44,"city":147,"state":27,"zip":148,"country":138,"countryCode":139,"cosmosGeoPoint":149,"geoPoint":153,"contacts":27},"Instytut \"Pomnik - Centrum Zdrowia Dziecka\"","Warsaw","04-730",{"type":51,"coordinates":150},[151,152],21.01178,52.22977,{"lat":152,"lon":151},{"facility":155,"status":44,"city":156,"state":27,"zip":157,"country":158,"countryCode":27,"cosmosGeoPoint":159,"geoPoint":163,"contacts":27},"Kocaeli University Research and Application Hospit","Kocaeli","6810","Turkey (Türkiye)",{"type":51,"coordinates":160},[161,162],27.51145,39.62497,{"lat":162,"lon":161},{"facility":165,"status":44,"city":166,"state":27,"zip":167,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":27},"Great Ormond Street Hospital for Children","London","WC1N 3JH","United Kingdom","UK",{"type":51,"coordinates":171},[172,173],-0.12574,51.50853,{"lat":173,"lon":172},{"type":176,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100454603","phase-3-a-study-to-evaluate-pharmacokinetics-efficacy-safety-tolerability-and-pharmacodynamics-of-satralizumab-in-pediatric-patients-with-aquaporin-4-antibody-positive-neuromyelitis-optica-spectrum-disorder-nmosd-100454603",false,"NCT05199688","A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)","A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)","SAkuraSun","Inclusion Criteria:\n\n* Age at screening 2-11 years, inclusive\n* Body weight at screening \\>=10 kg\n* For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception\n* Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening\n* Neurological stability for \\>=30 days prior to both screening and baseline\n* Expanded Disability Status Scale (EDSS) 0 to 6.5\n* For patients receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Evidence of other demyelinating disease mimicking NMOSD\n* Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline\n* Evidence of chronic active hepatitis B or C\n* Evidence of untreated latent or active tuberculosis (TB)\n* Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline\n* History of severe allergic reaction to a biologic agent","ALL","2 Years","11 Years",{"count":189,"type":190},8,"ESTIMATED","INTERVENTIONAL",[193],"PHASE3","This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.",[196,197],"Neuromyelitis Optica Spectrum Disorder","NMOSD","2026-06-05",{"date":200,"type":201},"2026-06-09","ACTUAL",{"date":203,"type":201},"2026-05-06",{"date":205,"type":190},"2029-09-12",{"name":5,"class":6},13]